HMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence

Jinlong Yin, Jun Kyum Kim, Jai Hee Moon, Samuel Beck, Dachuan Piao, Xun Jin, Sung Hak Kim, Young Chang Lim, Do Hyun Nam, Seungkwon You, Hyunggee Kim, Yun Jaie Choi

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Glioma stem cells (GSCs) are known to be maintained within a "vascular niche"; thereby, disruption of this microenvironment using antiangiogenesis agents is a promising therapeutic modality. However, this regimen leads to treatment failure and tumor recurrence in patients with glioblastoma multiforme (GBM). Therefore, more effective therapeutic approaches that can eradicate GSCs and the bulk tumors are needed. Toward this goal, we examined the antitumor effects of an antiangiogenesis approach combined with conventional chemotherapy on suppressing glioma xenograft growth. We established three genetically engineered mesenchymal stem cell (MSC) lines (GE-AF-MSCs) by stably transducing the gene encoding endostatin (an antiangiogenesis factor), the gene encoding secretable form of carboxylesterase 2 (sCE2, a prodrug-activating enzyme), or a mixture of both genes. Among the three GE-AF-MSC cell lines, injection of amniotic fluid (AF)-MSCs-endostatin-sCE2 cells into U87MG-EGFRvIII-driven orthotopic brain tumor and postsurgery tumor recurrence models, and subsequent CPT11 treatment yielded the strongest antitumor responses, including diminished angiogenesis, increased cell death, and a reduced Nestin-positive GSC population. Therefore, our antitumor strategy provides a novel basis for designing stem cell-mediated therapeutic approaches to target and eradicate GSCs and the bulk tumors.

Original languageEnglish
Pages (from-to)1161-1169
Number of pages9
JournalMolecular Therapy
Volume19
Issue number6
DOIs
Publication statusPublished - 2011 Jun 1

Fingerprint

Endostatins
Carboxylesterase
Heterografts
Glioma
Recurrence
Amniotic Fluid
Stem Cells
Neoplastic Stem Cells
Mesenchymal Stromal Cells
Genes
Cell Line
Nestin
Prodrugs
Therapeutics
Glioblastoma
Treatment Failure
Brain Neoplasms
Blood Vessels
Neoplasms
Cell Death

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

HMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence. / Yin, Jinlong; Kim, Jun Kyum; Moon, Jai Hee; Beck, Samuel; Piao, Dachuan; Jin, Xun; Kim, Sung Hak; Lim, Young Chang; Nam, Do Hyun; You, Seungkwon; Kim, Hyunggee; Choi, Yun Jaie.

In: Molecular Therapy, Vol. 19, No. 6, 01.06.2011, p. 1161-1169.

Research output: Contribution to journalArticle

Yin, J, Kim, JK, Moon, JH, Beck, S, Piao, D, Jin, X, Kim, SH, Lim, YC, Nam, DH, You, S, Kim, H & Choi, YJ 2011, 'HMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence', Molecular Therapy, vol. 19, no. 6, pp. 1161-1169. https://doi.org/10.1038/mt.2011.28
Yin, Jinlong ; Kim, Jun Kyum ; Moon, Jai Hee ; Beck, Samuel ; Piao, Dachuan ; Jin, Xun ; Kim, Sung Hak ; Lim, Young Chang ; Nam, Do Hyun ; You, Seungkwon ; Kim, Hyunggee ; Choi, Yun Jaie. / HMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence. In: Molecular Therapy. 2011 ; Vol. 19, No. 6. pp. 1161-1169.
@article{77be0d2f7c964208b2e53a510f89840c,
title = "HMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence",
abstract = "Glioma stem cells (GSCs) are known to be maintained within a {"}vascular niche{"}; thereby, disruption of this microenvironment using antiangiogenesis agents is a promising therapeutic modality. However, this regimen leads to treatment failure and tumor recurrence in patients with glioblastoma multiforme (GBM). Therefore, more effective therapeutic approaches that can eradicate GSCs and the bulk tumors are needed. Toward this goal, we examined the antitumor effects of an antiangiogenesis approach combined with conventional chemotherapy on suppressing glioma xenograft growth. We established three genetically engineered mesenchymal stem cell (MSC) lines (GE-AF-MSCs) by stably transducing the gene encoding endostatin (an antiangiogenesis factor), the gene encoding secretable form of carboxylesterase 2 (sCE2, a prodrug-activating enzyme), or a mixture of both genes. Among the three GE-AF-MSC cell lines, injection of amniotic fluid (AF)-MSCs-endostatin-sCE2 cells into U87MG-EGFRvIII-driven orthotopic brain tumor and postsurgery tumor recurrence models, and subsequent CPT11 treatment yielded the strongest antitumor responses, including diminished angiogenesis, increased cell death, and a reduced Nestin-positive GSC population. Therefore, our antitumor strategy provides a novel basis for designing stem cell-mediated therapeutic approaches to target and eradicate GSCs and the bulk tumors.",
author = "Jinlong Yin and Kim, {Jun Kyum} and Moon, {Jai Hee} and Samuel Beck and Dachuan Piao and Xun Jin and Kim, {Sung Hak} and Lim, {Young Chang} and Nam, {Do Hyun} and Seungkwon You and Hyunggee Kim and Choi, {Yun Jaie}",
year = "2011",
month = "6",
day = "1",
doi = "10.1038/mt.2011.28",
language = "English",
volume = "19",
pages = "1161--1169",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - HMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence

AU - Yin, Jinlong

AU - Kim, Jun Kyum

AU - Moon, Jai Hee

AU - Beck, Samuel

AU - Piao, Dachuan

AU - Jin, Xun

AU - Kim, Sung Hak

AU - Lim, Young Chang

AU - Nam, Do Hyun

AU - You, Seungkwon

AU - Kim, Hyunggee

AU - Choi, Yun Jaie

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Glioma stem cells (GSCs) are known to be maintained within a "vascular niche"; thereby, disruption of this microenvironment using antiangiogenesis agents is a promising therapeutic modality. However, this regimen leads to treatment failure and tumor recurrence in patients with glioblastoma multiforme (GBM). Therefore, more effective therapeutic approaches that can eradicate GSCs and the bulk tumors are needed. Toward this goal, we examined the antitumor effects of an antiangiogenesis approach combined with conventional chemotherapy on suppressing glioma xenograft growth. We established three genetically engineered mesenchymal stem cell (MSC) lines (GE-AF-MSCs) by stably transducing the gene encoding endostatin (an antiangiogenesis factor), the gene encoding secretable form of carboxylesterase 2 (sCE2, a prodrug-activating enzyme), or a mixture of both genes. Among the three GE-AF-MSC cell lines, injection of amniotic fluid (AF)-MSCs-endostatin-sCE2 cells into U87MG-EGFRvIII-driven orthotopic brain tumor and postsurgery tumor recurrence models, and subsequent CPT11 treatment yielded the strongest antitumor responses, including diminished angiogenesis, increased cell death, and a reduced Nestin-positive GSC population. Therefore, our antitumor strategy provides a novel basis for designing stem cell-mediated therapeutic approaches to target and eradicate GSCs and the bulk tumors.

AB - Glioma stem cells (GSCs) are known to be maintained within a "vascular niche"; thereby, disruption of this microenvironment using antiangiogenesis agents is a promising therapeutic modality. However, this regimen leads to treatment failure and tumor recurrence in patients with glioblastoma multiforme (GBM). Therefore, more effective therapeutic approaches that can eradicate GSCs and the bulk tumors are needed. Toward this goal, we examined the antitumor effects of an antiangiogenesis approach combined with conventional chemotherapy on suppressing glioma xenograft growth. We established three genetically engineered mesenchymal stem cell (MSC) lines (GE-AF-MSCs) by stably transducing the gene encoding endostatin (an antiangiogenesis factor), the gene encoding secretable form of carboxylesterase 2 (sCE2, a prodrug-activating enzyme), or a mixture of both genes. Among the three GE-AF-MSC cell lines, injection of amniotic fluid (AF)-MSCs-endostatin-sCE2 cells into U87MG-EGFRvIII-driven orthotopic brain tumor and postsurgery tumor recurrence models, and subsequent CPT11 treatment yielded the strongest antitumor responses, including diminished angiogenesis, increased cell death, and a reduced Nestin-positive GSC population. Therefore, our antitumor strategy provides a novel basis for designing stem cell-mediated therapeutic approaches to target and eradicate GSCs and the bulk tumors.

UR - http://www.scopus.com/inward/record.url?scp=79957897226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957897226&partnerID=8YFLogxK

U2 - 10.1038/mt.2011.28

DO - 10.1038/mt.2011.28

M3 - Article

VL - 19

SP - 1161

EP - 1169

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 6

ER -